These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2382632)

  • 1. The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system.
    Lloyd P; John VA; Signy M; Smith SE
    Am Heart J; 1990 Aug; 120(2):478-82. PubMed ID: 2382632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic comparison of an osmotic release oral metoprolol tablet and the metoprolol conventional tablet.
    Feliciano NR; Bouvet AA; Redalieu E; Castellana J; Luders RC; Schwartz DJ; Shum L; Zak S; Arnold JD; Leese PT
    Am Heart J; 1990 Aug; 120(2):483-9. PubMed ID: 2382633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man.
    Lecaillon JB; Massias P; Schoeller JP; Abadie F
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):245S-249S. PubMed ID: 4005130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food on the bioavailability of metoprolol from an OROS system; a study in healthy volunteers.
    van den Berg G; van Steveninck F; Gubbens-Stibbe JM; Schoemaker HC; de Boer AG; Cohen AF
    Eur J Clin Pharmacol; 1990; 39(3):315-6. PubMed ID: 2257873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osmotically controlled-delivery of metoprolol in man: in vivo performance of Oros systems with different durations of drug release.
    Godbillon J; Gerardin A; Richard J; Leroy D; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):213S-218S. PubMed ID: 4005125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.
    Hoffmann KJ; Regårdh CG; Aurell M; Ervik M; Jordö L
    Clin Pharmacokinet; 1980; 5(2):181-91. PubMed ID: 7363533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable isotope methodology for studying the performance of metoprolol Oros tablets in comparison to conventional and slow release formulations.
    Richard J; Cardot JM; Godbillon J
    Eur J Drug Metab Pharmacokinet; 1994; 19(4):375-80. PubMed ID: 7737240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations.
    Mistry B; Leslie JL; Eddington ND
    Chirality; 2002 May; 14(4):297-304. PubMed ID: 11968069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration.
    Warrington SJ; Barclay SP; John VA; Shotton PA; Wardle HM; Good W
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):219S-224S. PubMed ID: 4005126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oros controlled-release formulations of metoprolol: an approach to the development of a system for once daily administration.
    Good W; Leeson LJ; Zak SL; Wagner WE; Meeker JB; Arnold JD
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):231S-238S. PubMed ID: 4005128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.
    Kendall MJ; Jack DB; Woods KL; Laugher SJ; Quarterman CP; John VA
    Br J Clin Pharmacol; 1982 Mar; 13(3):393-8. PubMed ID: 7059440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes.
    Bae SH; Lee JK; Cho DY; Bae SK
    J Sep Sci; 2014 Jun; 37(11):1256-64. PubMed ID: 24648255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of AST-120 on the single-dose pharmacokinetics of metoprolol extended-release tablets in healthy subjects.
    Inoue S; Shimizu M; Arita K; Akimoto K
    Drug Metabol Drug Interact; 2014; 29(2):115-21. PubMed ID: 24643911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog.
    Regårdh CG; Ek L; Hoffmann KJ
    J Pharmacokinet Biopharm; 1979 Oct; 7(5):471-9. PubMed ID: 43384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.
    Grainger SL; John VA; Shotton PA; Smith SE
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):239S-244S. PubMed ID: 4005129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.
    Plosker GL; Clissold SP
    Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics.
    Xu T; Bao S; Geng P; Luo J; Yu L; Pan P; Chen Y; Hu G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():60-6. PubMed ID: 24018320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing.
    Sandberg A; Abrahamsson B; Svenheden A; Olofsson B; Bergstrand R
    Pharm Res; 1993 Jan; 10(1):28-34. PubMed ID: 8430057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.
    Johnsson G; Jordö L; Lundborg P; Regårdh CG; Rönn O
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):292-7. PubMed ID: 7000717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary effects of long-term beta 2-blockade in healthy subjects: comparative study of metoprolol OROS.
    Bauer K; Rakusan S; Kaik G
    Am Heart J; 1990 Aug; 120(2):473-7. PubMed ID: 1974382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.